PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
503.87 - 512.55
344.79 - 555.45
23.62M / 20.39M (Avg.)
37.30 | 13.67
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
12.92%
Net income growth above 1.5x CRWV's 7.67%. David Dodd would see a clear bottom-line advantage if it is backed by stable operations.
-5.26%
Negative yoy D&A while CRWV is 26.15%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
13.33%
Slight usage while CRWV is negative at -110.52%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
-950.00%
Negative yoy inventory while CRWV is 0.00%. Joel Greenblatt would see a near-term cash advantage if top-line doesn't suffer.
No Data
No Data available this quarter, please select a different quarter.
46.55%
Lower 'other working capital' growth vs. CRWV's 112.72%. David Dodd would see fewer unexpected short-term demands on cash.
No Data
No Data available this quarter, please select a different quarter.
17.65%
Some CFO growth while CRWV is negative at -510.76%. John Neff would note a short-term liquidity lead over the competitor.
-4.08%
Both yoy lines negative, with CRWV at -74.30%. Martin Whitman would suspect a cyclical or broad capital spending slowdown in the niche.
No Data
No Data available this quarter, please select a different quarter.
-158.77%
Negative yoy purchasing while CRWV stands at 0.00%. Joel Greenblatt sees a near-term liquidity advantage unless competitor’s new investments produce outsized returns.
No Data
No Data available this quarter, please select a different quarter.
166.67%
Growth well above CRWV's 202.79%. Michael Burry would suspect heavier intangible or side spending overshadowing competitor’s approach, risking short-term FCF.
-102.37%
Both yoy lines negative, with CRWV at -70.42%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
No Data
No Data available this quarter, please select a different quarter.
104.82%
Stock issuance far above CRWV's 4.88%. Michael Burry flags a significant dilution risk vs. competitor’s approach unless ROI is very high.
100.00%
Buyback growth of 100.00% while CRWV is zero at 0.00%. Bruce Berkowitz sees a modest per-share advantage that might accumulate if the stock is below intrinsic value.